Literature DB >> 33685501

Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation.

Claire E Raphael1,2, Frances Mitchell3, Gajen Sunthar Kanaganayagam3, Alphonsus C Liew3, Elisa Di Pietro4, Miguel Silva Vieira3, Lina Kanapeckaite3, Simon Newsome5, John Gregson5, Ruth Owen5, Li-Yueh Hsu6, Vassilis Vassiliou3,7, Robert Cooper3, Aamir Ali Mrcp3, Tevfik F Ismail8, Brandon Wong3, Kristi Sun3, Peter Gatehouse3, David Firmin3, Stuart Cook3,9, Michael Frenneaux7, Andrew Arai6, Rory O'Hanlon10, Dudley J Pennell3, Sanjay K Prasad3.   

Abstract

INTRODUCTION: Heart failure (HF) in hypertrophic cardiomyopathy (HCM) is associated with high morbidity and mortality. Predictors of HF, in particular the role of myocardial fibrosis and microvascular ischemia remain unclear. We assessed the predictive value of cardiovascular magnetic resonance (CMR) for development of HF in HCM in an observational cohort study.
METHODS: Serial patients with HCM underwent CMR, including adenosine first-pass perfusion, left atrial (LA) and left ventricular (LV) volumes indexed to body surface area (i) and late gadolinium enhancement (%LGE- as a % of total myocardial mass). We used a composite endpoint of HF death, cardiac transplantation, and progression to NYHA class III/IV.
RESULTS: A total of 543 patients with HCM underwent CMR, of whom 94 met the composite endpoint at baseline. The remaining 449 patients were followed for a median of 5.6 years. Thirty nine patients (8.7%) reached the composite endpoint of HF death (n = 7), cardiac transplantation (n = 2) and progression to NYHA class III/IV (n = 20). The annual incidence of HF was 2.0 per 100 person-years, 95% CI (1.6-2.6). Age, previous non-sustained ventricular tachycardia, LV end-systolic volume indexed to body surface area (LVESVI), LA volume index ; LV ejection fraction, %LGE and presence of mitral regurgitation were significant univariable predictors of HF, with LVESVI (Hazard ratio (HR) 1.44, 95% confidence interval (95% CI) 1.16-1.78, p = 0.001), %LGE per 10% (HR 1.44, 95%CI 1.14-1.82, p = 0.002) age (HR 1.37, 95% CI 1.06-1.77, p = 0.02) and mitral regurgitation (HR 2.6, p = 0.02) remaining independently predictive on multivariable analysis. The presence or extent of inducible perfusion defect assessed using a visual score did not predict outcome (p = 0.16, p = 0.27 respectively). DISCUSSION: The annual incidence of HF in a contemporary ambulatory HCM population undergoing CMR is low. Myocardial fibrosis and LVESVI are strongly predictive of future HF, however CMR visual assessment of myocardial perfusion was not.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Fibrosis; Heart failure; Hypertrophic cardiomyopathy; Microvascular ischemia; Myocardial perfusion; Prognosis

Year:  2021        PMID: 33685501      PMCID: PMC7941878          DOI: 10.1186/s12968-021-00720-9

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  34 in total

1.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography.

Authors:  P Camici; G Chiriatti; R Lorenzoni; R C Bellina; R Gistri; G Italiani; O Parodi; P A Salvadori; N Nista; L Papi
Journal:  J Am Coll Cardiol       Date:  1991-03-15       Impact factor: 24.094

2.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Iacopo Olivotto; Caitlin Harrigan; Evan Appelbaum; C Michael Gibson; John R Lesser; Tammy S Haas; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circulation       Date:  2011-06-13       Impact factor: 29.690

3.  Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.

Authors:  Kevin M Harris; Paolo Spirito; Martin S Maron; Andrey G Zenovich; Francesco Formisano; John R Lesser; Shannon Mackey-Bojack; Warren J Manning; James E Udelson; Barry J Maron
Journal:  Circulation       Date:  2006-07-10       Impact factor: 29.690

4.  Stress hypoperfusion and tissue injury in hypertrophic cardiomyopathy: spatial characterization using high-resolution 3-tesla magnetic resonance imaging.

Authors:  Chung Chun Tyan; Sarah Armstrong; David Scholl; John Stirrat; Kimberly Blackwood; Omar El-Sherif; Terry Thompson; Gerald Wisenberg; Frank S Prato; Aaron So; Ting Yim Lee; Maria Drangova; James A White
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-14       Impact factor: 7.792

Review 5.  Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.

Authors:  Roberto Spoladore; Martin S Maron; Rossella D'Amato; Paolo G Camici; Iacopo Olivotto
Journal:  Eur Heart J       Date:  2012-06-19       Impact factor: 29.983

6.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

7.  Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation.

Authors:  J Shirani; B J Maron; R O Cannon; S Shahin; W C Roberts
Journal:  Am J Cardiol       Date:  1993-08-15       Impact factor: 2.778

8.  Myocardial infarct sizing by late gadolinium-enhanced MRI: Comparison of manual, full-width at half-maximum, and n-standard deviation methods.

Authors:  Lin Zhang; Olivier Huttin; Pierre-Yves Marie; Jacques Felblinger; Marine Beaumont; Christian DE Chillou; Nicolas Girerd; Damien Mandry
Journal:  J Magn Reson Imaging       Date:  2016-04-20       Impact factor: 4.813

9.  Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial.

Authors:  John P Greenwood; Neil Maredia; John F Younger; Julia M Brown; Jane Nixon; Colin C Everett; Petra Bijsterveld; John P Ridgway; Aleksandra Radjenovic; Catherine J Dickinson; Stephen G Ball; Sven Plein
Journal:  Lancet       Date:  2011-12-22       Impact factor: 79.321

10.  Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study.

Authors:  Tevfik F Ismail; Li-Yueh Hsu; Anders M Greve; Carla Gonçalves; Andrew Jabbour; Ankur Gulati; Benjamin Hewins; Niraj Mistry; Ricardo Wage; Michael Roughton; Pedro F Ferreira; Peter Gatehouse; David Firmin; Rory O'Hanlon; Dudley J Pennell; Sanjay K Prasad; Andrew E Arai
Journal:  J Cardiovasc Magn Reson       Date:  2014-08-12       Impact factor: 5.364

View more
  2 in total

Review 1.  The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy.

Authors:  Sanjay Sivalokanathan
Journal:  Diagnostics (Basel)       Date:  2022-01-26

Review 2.  Major Clinical Issues in Hypertrophic Cardiomyopathy.

Authors:  Hyung-Kwan Kim; Sang Chol Lee; Hyun-Jung Lee; Jihoon Kim; Sung-A Chang; Yong-Jin Kim
Journal:  Korean Circ J       Date:  2022-08       Impact factor: 3.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.